Showing results (41-50 of 344) with videos related to

Sort By:
Pageof 35
Inflammation & Allergy Drug Targets|March 17, 2010
Predictive factors for disability as evaluated by the health assessment questionnaire in rheumatoid arthritis: a literature reviewEric Toussirot
Expert Opinion on Pharmacotherapy|January 19, 2017
New treatment options and emerging drugs for axial spondyloarthritis: biological and targeted synthetic agentsEric Toussirot
Expert Opinion on Biological Therapy|December 1, 2017
Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritisEric Toussirot
Frontiers in Medicine|December 3, 2021
The Risk of Cardiovascular Diseases in Axial Spondyloarthritis. Current InsightsEric Toussirot
Pharmaceuticals (Basel, Switzerland)|March 26, 2022
The Use of Janus Kinase Inhibitors in Axial Spondyloarthritis: Current InsightsEric Toussirot
Frontiers in Endocrinology|January 11, 2021
Mini-Review: The Contribution of Adipokines to Joint Inflammation in Inflammatory Rheumatic DiseasesEric Toussirot
Biomedicines|February 25, 2023
The Influence of Adipokines on Radiographic Damage in Inflammatory Rheumatic DiseasesEric Toussirot
Expert Opinion on Pharmacotherapy|May 17, 2019
Pharmacological management of axial spondyloarthritis in adultsEric Toussirot
Joint Bone Spine|July 26, 2005
Infliximab continuation rates in patients with rheumatoid arthritis in everyday practiceDaniel Wendling, Guewen-Edouard Materne, Fabrice Michel, et al.
Plos One|September 17, 2013
Imbalance between HAT and HDAC activities in the PBMCs of patients with ankylosing spondylitis or rheumatoid arthritis and influence of HDAC inhibitors on TNF alpha productionEric Toussirot, Wasim Abbas, Kashif Aziz Khan, et al.
Pageof 35